ELF3 is highly expressed in head and neck tumors and upregulates the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) to attenuate the antiproliferative effects of EGFR/HER2 tyrosine kinase inhibitors (lapatinib and afatinib) [28]. Here, EGFR is linked to head and neck neoplasm.